<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864067</url>
  </required_header>
  <id_info>
    <org_study_id>FONDECYT 11201291</org_study_id>
    <nct_id>NCT04864067</nct_id>
  </id_info>
  <brief_title>No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer</brief_title>
  <acronym>NOAHS-ARC</acronym>
  <official_title>No Operation After Short Course Equivalent Dose (Ht) Radiation Therapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer: The Prospective, Single Arm NOAHS-ARC Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servicio de Salud Metropolitano Sur Oriente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servicio de Salud Metropolitano Sur Oriente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to explore the hypothesis that in patients with a Locally advanced&#xD;
      rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short&#xD;
      course radiotherapy (5x5Gy) followed by neoadjuvant consolidation chemotherapy is associated&#xD;
      with a higher rate of pathological clinical response and sustained (&gt;1year) complete clinical&#xD;
      response when compared to an historical cohort treated with long course chemoradiation&#xD;
      therapy (CRT), total mesorectal excision (TME) and adjuvant chemotherapy (ACT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-operative management with a Watch and Wait (W&amp;W) strategy has been advocated for selected&#xD;
      patients with a locally advanced rectal cancer (LARC) and a complete clinical response (cCR)&#xD;
      after neoajuvant (NA) treatment.&#xD;
&#xD;
      In this context, total neoadjuvant therapy (TNT), i.e the use of radiotherapy and full dose&#xD;
      of post-operative chemotherapy as part of NA treatment, has emerged as a strategy to enhance&#xD;
      treatment response.&#xD;
&#xD;
      Currently, TNT has reported higher rates of pCR and organ preservation when compared to&#xD;
      current standard of care. However, the best TNT strategy is still unknown. We therefore&#xD;
      hypothesize that in LARC patients, the use of a TNT strategy based on short course RT&#xD;
      followed by consolidation chemotherapy is associated with a higher rate of pCR and sustained&#xD;
      (&gt;1year) cCR when compared to an historic cohort.&#xD;
&#xD;
      The main aim of the present proposal is to assess the effects of a standardized TNT model in&#xD;
      LARC patients as a strategy for enhanced pCR/sustained cCR. For this purpose, we propose the&#xD;
      following experimental model: In primary Aim 1 we will study if the effects of a TNT strategy&#xD;
      over patients with a LARC enhance the rate of pCR/sustained cCR by (1) evaluating the&#xD;
      compliance and toxicity of a TNT strategy as a proof of concept of its applicability, (2)&#xD;
      assessing the rate of cCR at the end of TNT and (3) assessing the rate of pCR in the&#xD;
      surgically managed subgroup and sustained cCR (&gt;1year) in the W&amp;W subgroup. Additionally, in&#xD;
      primary Aim 2, we will determine if patients with a W&amp;W strategy have better functional&#xD;
      outcomes and quality of life (QoL) than patients treated with TME after TNT by (1) using&#xD;
      validated questionnaires for the evaluation of bowel, sexual and urinary function for W&amp;W and&#xD;
      TME patients and (2) by evaluating the QoL using a widely-used standardized questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pathological and sustained clinical response</measure>
    <time_frame>3 years</time_frame>
    <description>Combined number of patients with pathological response in the surgical specimen and patients in a Watch and Wait protocol with a sustained clinical response longer than a year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life and Funcional Outcomes</measure>
    <time_frame>3 years</time_frame>
    <description>Standardized evaluation using validated questionnaires comparing patients undergoing TME versus WW patients in the cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Short Course Radiotherapy and Consolidation Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive short course radiotherapy (5x5 Gy) during 1 week. Between 7 to 14 days after radiotherapy, patient will receive 9 cycles of FOLFOX. CapeOX may be given as alternative for FOLFOX.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Consolidation Chemotherapy</description>
    <arm_group_label>Short Course Radiotherapy and Consolidation Chemotherapy</arm_group_label>
    <other_name>All Brands</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluoracil</intervention_name>
    <description>Consolidation Chemotherapy</description>
    <arm_group_label>Short Course Radiotherapy and Consolidation Chemotherapy</arm_group_label>
    <other_name>All Brands</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Consolidation Chemotherapy</description>
    <arm_group_label>Short Course Radiotherapy and Consolidation Chemotherapy</arm_group_label>
    <other_name>All Brands</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Consolidation Chemotherapy</description>
    <arm_group_label>Short Course Radiotherapy and Consolidation Chemotherapy</arm_group_label>
    <other_name>All Brands</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>5x5 Gy</intervention_name>
    <description>Neoadjuvant Radiotherapy</description>
    <arm_group_label>Short Course Radiotherapy and Consolidation Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Questionnaires</intervention_name>
    <description>Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)</description>
    <arm_group_label>Short Course Radiotherapy and Consolidation Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DRE/ Endoscopy</intervention_name>
    <description>Flexible Sigmoidoscopy and Digital Rectal Exam</description>
    <arm_group_label>Short Course Radiotherapy and Consolidation Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of adenocarcinoma of the rectum&#xD;
&#xD;
          -  Clinical Stage II (T3-4, N-) or Stage III (any T, N+) based on Magnetic Resonance&#xD;
             Imaging (MRI)&#xD;
&#xD;
          -  Tumors &lt; 7cm from anal verge (palpable)&#xD;
&#xD;
          -  No prior history of rectal cancer&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with tumors &gt;7cm from anal verge&#xD;
&#xD;
          -  ECOG &gt;1,&#xD;
&#xD;
          -  Contraindication for chemotherapy: Hemoglobin &lt;8, White Blood Count &lt;4000, Platelets&#xD;
             &lt;100,000, Creatinine Clearance &lt;50ml/min, Total Bilirubin &lt;5mg/dl,&#xD;
&#xD;
          -  Stage IV at diagnosis&#xD;
&#xD;
          -  Coronary artery disease, either no treated or recent acute coronary syndrome in the&#xD;
             last 12 months.&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Previous pelvic radiotherapy&#xD;
&#xD;
          -  Prior rectal cancer treatment&#xD;
&#xD;
          -  Pregnancy or nursery&#xD;
&#xD;
          -  Any contraindications to MRI (e.g. patients with pacemakers)&#xD;
&#xD;
          -  Indication of pelvic exenteration&#xD;
&#xD;
          -  Impossibility to consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe F Quezada-Diaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Asistencial Doctor Sótero del Rio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole M Caire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Asistencial Doctor Sótero Del Río</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe F Quezada-Diaz, MD</last_name>
    <phone>+ 562 25762401</phone>
    <email>ffquezad@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole M Caire, MD</last_name>
    <phone>+ 562 25762401</phone>
    <email>cairenicole@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Asistencial Doctor Sótero del Rio</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe F Quezada-Diaz, MD</last_name>
      <phone>+ 562 25762401</phone>
      <email>ffquezad@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nicolle M Caire, MD</last_name>
      <email>cairenicole@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital La Florida</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose A Hernandez, MD</last_name>
      <email>drjoseanhernandez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Padre Hurtado</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Pradenas, MD</last_name>
      <email>sebapradenas@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Neoadjuvant therapy</keyword>
  <keyword>Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

